Which antibiotics are safe and appropriate for treating an uncomplicated urinary tract infection in an adult with chronic kidney disease, and how should dosing be adjusted based on estimated glomerular filtration rate?

CKD-Safe Antibiotics for UTI

For uncomplicated cystitis in CKD patients, nitrofurantoin 100 mg twice daily for 5 days is the preferred first-line agent, with fosfomycin 3g single dose as an excellent alternative; trimethoprim-sulfamethoxazole should only be used if local resistance is <20% and requires dose adjustment when GFR <30 mL/min/1.73m².

Uncomplicated Cystitis in CKD

First-Line Agents (in order of preference):

Nitrofurantoin 1, 2, 1, 3

• Dose: 100 mg twice daily for 5 days
• CKD considerations: Safe across most CKD stages
• Efficacy: 88-93% clinical cure, 86-92% bacterial cure
• Key advantage: Minimal resistance and collateral damage
• Critical caveat: The KDIGO guideline 4 notes to reduce dose when GFR <45 mL/min/1.73m² and use with caution when GFR <15 mL/min/1.73m². However, recent evidence supports its use even in moderate CKD for short courses

Fosfomycin trometamol 1, 2, 1, 3

• Dose: 3g single oral dose
• CKD considerations: No dose adjustment needed; single-dose minimizes exposure
• Efficacy: 91% clinical cure, though slightly lower microbiologic cure (78-80%) than nitrofurantoin
• Key advantage: Excellent safety profile in CKD, minimal resistance

Trimethoprim-sulfamethoxazole (TMP-SMX) 1, 2, 1, 5

• Dose: 160/800 mg (1 double-strength tablet) twice daily for 3 days
• CKD dose adjustment: 5
  • GFR 15-30 mL/min: Reduce to half dose
  • GFR <15 mL/min: Half dose or use alternative agent
• Use only if: Local E. coli resistance <20% AND patient not recently exposed to TMP-SMX
• Efficacy: 93-94% cure when organism is susceptible

Second-Line Agents:

Pivmecillinam 1, 3

• Dose: 400 mg twice daily for 3 days
• Efficacy: 73-79% (lower than first-line agents)
• Availability: Limited to some European countries; not available in North America

Agents to AVOID as First-Line:

Fluoroquinolones (ciprofloxacin, levofloxacin) 1, 2, 1

• Why avoid: High propensity for collateral damage (C. difficile, resistance development)
• When to consider: Only for resistant organisms or when first-line agents cannot be used
• Dose adjustments: 4, 5
  • Ciprofloxacin: Reduce by 50% when GFR <15 mL/min/1.73m²
  • Levofloxacin: 500mg loading dose, then 250mg q24h if GFR 50-80 mL/min; 250mg q48h if GFR <50 mL/min

Beta-lactams 1

• Why second-line: Less well-studied, lower efficacy (82-89%)
• If used: Amoxicillin-clavulanate, cefdinir, cefpodoxime for 3-7 days
• CKD consideration: Generally safe but require dose adjustment based on specific agent

Uncomplicated Pyelonephritis in CKD

Oral Therapy (Outpatient):

Fluoroquinolones 2, 6, 3

• Ciprofloxacin: 500-750 mg twice daily for 7 days
• Levofloxacin: 750 mg once daily for 5 days
• Dose adjustment: 5
  • Levofloxacin: If GFR 50-80 mL/min: 500mg loading, then 250mg q24h
  • If GFR <50 mL/min: 500mg loading, then 250mg q48h

TMP-SMX 2, 6, 3

• Dose: 160/800 mg twice daily for 14 days
• CKD adjustment: Same as for cystitis
• Note: Longer duration (14 days) required compared to fluoroquinolones

Parenteral Therapy (Hospitalized):

First-line options 6:

• Ceftriaxone: 1-2g once daily (higher dose recommended)
• Ciprofloxacin: 400mg IV twice daily
• Levofloxacin: 750mg IV once daily
• Gentamicin: 5 mg/kg once daily (with dose adjustment)
• Piperacillin-tazobactam: 2.5-4.5g three times daily

Aminoglycoside dosing in CKD 4, 5:

• Reduce dose and/or increase interval when GFR <60 mL/min/1.73m²
• Monitor serum levels (trough and peak)
• Avoid concomitant ototoxic agents (furosemide)
• Once-daily dosing preferred for preserved renal function

Critical CKD-Specific Considerations:

Medication Safety:

1. Assess GFR before prescribing 4

   • Use eGFR for initial assessment
   • Consider measuring GFR directly for high-consequence decisions

2. Monitor during treatment 4

   • Reassess GFR and electrolytes within 1 week if using nephrotoxic agents
   • Temporarily suspend nephrotoxic antibiotics during intercurrent illness

3. Avoid nephrotoxic combinations 4

   • NSAIDs + aminoglycosides
   • Multiple nephrotoxic agents simultaneously

Agents Requiring Special Caution:

Penicillins 4

• Risk of crystalluria when GFR <15 mL/min/1.73m² with high doses
• Neurotoxicity with benzylpenicillin (maximum 6g/day)

Macrolides 4

• Reduce dose by 50% when GFR <30 mL/min/1.73m²

Tetracyclines 4

• Reduce dose when GFR <45 mL/min/1.73m²
• Can exacerbate uremia

Common Pitfalls to Avoid:

1. Using nitrofurantoin in severe CKD: While traditionally avoided in GFR <30 mL/min, short 5-day courses may be acceptable for moderate CKD. Absolutely avoid in GFR <15 mL/min/1.73m²

2. Empiric fluoroquinolone use: Reserve for situations where first-line agents truly cannot be used due to resistance or allergy

3. Underdosing in early CKD: Patients with GFR >45 mL/min generally do not require dose adjustment for most UTI antibiotics

4. Forgetting to adjust TMP-SMX: This commonly used agent requires dose reduction at GFR <30 mL/min/1.73m²

5. Using oral fosfomycin for pyelonephritis: Insufficient data support its use for upper tract infections; reserve for cystitis only 6, 3

Algorithm for Antibiotic Selection:

Step 1: Determine infection type (cystitis vs. pyelonephritis)

Step 2: Calculate eGFR

Step 3: For cystitis:

• If GFR ≥30 mL/min → Nitrofurantoin 100mg BID x 5 days OR Fosfomycin 3g single dose
• If GFR 15-30 mL/min → Fosfomycin 3g single dose (preferred) OR TMP-SMX half-dose if resistance <20%
• If GFR <15 mL/min → Fosfomycin 3g single dose OR culture-directed therapy

Step 4: For pyelonephritis:

• If GFR ≥50 mL/min → Levofloxacin 750mg daily x 5 days OR Ciprofloxacin 500-750mg BID x 7 days
• If GFR 30-50 mL/min → Levofloxacin 500mg loading then 250mg daily OR TMP-SMX 14 days with dose adjustment
• If GFR <30 mL/min → Consider hospitalization for IV therapy with appropriate dose adjustments

Step 5: Reassess clinical response at 48-72 hours and adjust based on culture results